KR KRSNAA
Krsnaa Diagnostics Q1 2026
KRKRSNAA

Krsnaa Diagnostics Q1 FY26 results (Apr–Jun 2025) and concall

Healthcare · Concall AI · Call held 12 Aug 2025

Management summary

  • Krsnaa Diagnostics reported a strong Q1 FY26, with revenue growing 13% YoY to ₹193 crores and EBITDA margin expanding to 27%.
  • The company secured a significant Rajasthan PPP contract, projecting ₹300-350 crores in annualized revenue, and saw its retail business accelerate, now contributing 6% to total revenues.
  • While overall volume growth was subdued, management expects improvement in coming quarters and is focused on leveraging its PPP backbone for retail expansion and maintaining cost leadership.

Source: Inve concall analysis and management guidance record.

Highlights

  • Revenue grew 13% YoY to ₹193 crores (INR 1,930 million) in Q1 FY26, demonstrating robust growth.

  • EBITDA margin expanded by 120 basis points to 27%, with EBITDA growing 19% YoY to ₹52.4 crores (INR 524 million).

  • Profit After Tax (PAT) increased 15% YoY to ₹20.5 crores (INR 205 million), achieving an 11% margin.

  • The company secured the Rajasthan PPP contract, involving an investment of ₹200-250 crores and an annualized revenue potential of ₹300-350 crores.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Revenue9 10 8
EBITDA48 53 50
Net profit22 21 20
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Overall Revenue Growth Revenue · FY26 · Medium confidence better than industry average (higher than 15-16%)

Profitability

  • EBITDA Margin Profitability · FY26 · High confidence 25-26%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Rajasthan PPP Contract Investment, Timeline, and Revenue Potential Direct
In terms of the project ramp-up, we expect the ramp-up to start in the next couple of months, which will probably take about 6 to 9 months, and the revenue will start flowing from the next financial year. ... we look at CAPEX in the range of about INR 200 crores to INR 250 crores

Analyst sought clarity on the financial outlay and expected returns from the newly awarded, significant Rajasthan contract, which management provided with specific numbers and timelines.

Asked by Surya Patra

Subdued Volume Growth and Future Outlook Partial
If you see the volume that you are referring to subdued is majorly which if you compare on a like-for-like, it was the BMC, which was in the past. But also, there are some of the projects that we suspend the operations, these have resulted. But now if you see on the retail side a

Analyst challenged the company on its ~4% volume growth, which is below industry average. Management attributed it to past BMC contract and suspended projects, indicating retail growth is compensating.

Asked by Lokesh Manik

Unlock risks & concerns, Q2 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 4 risks, concerns & management red flags
  • 5 watchlist triggers for Q2 FY26
  • +7 more guidance targets & verbatim management quotes
  • +4 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image